We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,357
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
Park National Corp
PRK
$3.75B
| $2.39M | ﹤0.01% |
23,306
+536
| +2% | +$53.5K |
|
|
S
1702
DELISTED
Sprint Corporation
S
| $2.38M | ﹤0.01% |
457,008
-257
| -0.1% | -$1.51K |
|
1703
MGP Ingredients
MGPI
$387M
| $2.37M | ﹤0.01% |
49,004
+2,463
| +5% | +$115K |
|
1704
BJ's Restaurants
BJRI
$1.46B
| $2.37M | ﹤0.01% |
62,488
+733
| +1% | +$28.1K |
|
1705
Karyopharm Therapeutics
KPTI
$43.5M
| $2.37M | ﹤0.01% |
8,248
+521
| +7% | +$113K |
|
|
WLL
1706
DELISTED
Whiting Petroleum Corporation
WLL
| $2.37M | ﹤0.01% |
4,307
+250
| +6% | +$121K |
|
1707
Harmonic Inc
HLIT
$1.31B
| $2.37M | ﹤0.01% |
303,673
+17,218
| +6% | +$129K |
|
1708
Brown-Forman Class A
BF.A
$13.2B
| $2.37M | ﹤0.01% |
37,693
+544
| +1% | +$33.4K |
|
1709
AppFolio
APPF
$6.84B
| $2.36M | ﹤0.01% |
21,504
+380
| +2% | +$38.8K |
|
1710
Zumiez
ZUMZ
$333M
| $2.36M | ﹤0.01% |
68,362
+3,640
| +6% | +$115K |
|
|
ITCI
1711
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.35M | ﹤0.01% |
68,361
+1,017
| +2% | +$12.2K |
|
|
AGR
1712
DELISTED
Avangrid, Inc.
AGR
| $2.34M | ﹤0.01% |
45,730
+353
| +0.8% | +$17.6K |
|
1713
Pitney Bowes
PBI
$2.48B
| $2.33M | ﹤0.01% |
577,848
+25,689
| +5% | +$118K |
|
|
AAWW
1714
DELISTED
Atlas Air Worldwide Holdings, Inc.
AAWW
| $2.33M | ﹤0.01% |
84,399
+4,795
| +6% | +$120K |
|
1715
HealthStream
HSTM
$821M
| $2.33M | ﹤0.01% |
85,505
+4,024
| +5% | +$111K |
|
|
ESPR
1716
DELISTED
Esperion Therapeutics
ESPR
| $2.32M | ﹤0.01% |
38,951
+2,834
| +8% | +$127K |
|
1717
Agios Pharmaceuticals
AGIO
$1.92B
| $2.32M | ﹤0.01% |
48,586
+4,086
| +9% | +$154K |
|
1718
SITE Centers
SITC
$165M
| $2.32M | ﹤0.01% |
211,954
+9,768
| +5% | +$111K |
|
|
ABTX
1719
DELISTED
Allegiance Bancshares
ABTX
| $2.32M | ﹤0.01% |
61,644
+33,622
| +120% | +$1.18M |
|
1720
Ethan Allen Interiors
ETD
$602M
| $2.31M | ﹤0.01% |
121,021
+4,435
| +4% | +$82.6K |
|
|
AIMT
1721
DELISTED
Aimmune Therapeutics
AIMT
| $2.3M | ﹤0.01% |
68,831
+4,941
| +8% | +$138K |
|
1722
DXP Enterprises
DXPE
$2.87B
| $2.3M | ﹤0.01% |
57,849
+3,199
| +6% | +$119K |
|
|
CHK
1723
DELISTED
Chesapeake Energy Corporation
CHK
| $2.3M | ﹤0.01% |
13,938
-288
| -2% | -$57.9K |
|
|
FIT
1724
DELISTED
Fitbit, Inc. Class A common stock
FIT
| $2.3M | ﹤0.01% |
350,238
+8,469
| +2% | +$49.7K |
|
|
STAY
1725
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
| $2.3M | ﹤0.01% |
154,534
+5,561
| +4% | +$81K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.